Vaccines or Immunotherapy for Viruses
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: closed (29 February 2024) | Viewed by 5546
Special Issue Editors
Interests: Standard researches and quality control of Japanese encephalitis vaccine; rabies vaccine for human use; yellow fever vaccine; forest encephalitis vaccine; ebola vaccine; adenovirus vector and mRNA based COVID-19 vaccine; dengue vaccine; SFTS vaccine and Zika vaccine, and so on
Special Issue Information
Dear Colleagues,
Immunotherapy involves using the body's own immune system to fight infections. By focusing on pathogens such as novel coronavirus, influenza viruses, HIV, hepatitis B viruses, arboviruses, Mycobacterium tuberculosis, and other pathogens, as well as future pathogens, the pathogenesis and drug resistance mechanism of infection are analyzed from the perspectives of pathogen evolution, pathogen host–interaction, molecular machine structure, and host immunologic. Based on this, detection and diagnosis technologies and products have been developed. Researchers in this field seek to design a new generation of especially broad-spectrum preventive vaccines, screen lead drugs and therapeutic antibodies, develop new therapies and strategies for the treatment of drug-resistant bacteria, and promote clinical transformation; at the same time, explore and develop tumor treatment strategies based on recombinant virus vectors and immune cells.
Based on the major needs of the prevention, diagnosis, and treatment of important infectious diseases, researchers make comprehensive use of cutting-edge technologies and means such as structural biology, bioinformatics, immunologic, pathogen genetic engineering, and synthetic biology to conduct in-depth research on basic scientific issues, such as pathogen invasion, pathogenicity, and pathogen–host interaction, and produce new technologies or products, such as detection and diagnosis, preventive vaccines and therapeutic drugs to provide tools for the eradication of sudden and serious infectious diseases and for biosafety defense purposes.
The purpose of this Special Issue is to provide a comprehensive collection of these reviews, articles, opinions, and other types of articles.
We look forward to receiving your submissions.
Prof. Dr. Yuhua Li
Prof. Dr. Maria Grazia Cusi
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- viruses
- arboviruses
- tuberculosis
- pathogens
- vaccine
- immune
